Molecular and Clinicopathological Characteristics of Lung Cancer Concomitant Chronic Obstructive Pulmonary Disease (COPD)

References

• Mouronte-Roibás C, Leiro-Fernández V, Ruano-Raviña A, et al. Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study. Respir Res. 2019;20(1):198. doi:10.1186/s12931-019-1155-2
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Labaki WW, Rosenberg SR, Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17–itc32. doi:10.7326/AITC202008040
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/s0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24–36. doi:10.1164/rccm.202009-3533SO
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/s0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Transl Lung Cancer Res. 2018;7(3):347–360. doi:10.21037/tlcr.2018.05.04
   PubMed Web of Science ®Google Scholar
• Sandri BJ, Kaplan A, Hodgson SW, et al. Multi-omic molecular profiling of lung cancer in COPD. Eur Respir J. 2018;52(1):1702665. doi:10.1183/13993003.02665-2017
   PubMed Web of Science ®Google Scholar
• Gao YH, Guan WJ, Liu Q, et al. Impact of COPD and emphysema on survival of patients with lung cancer: a meta-analysis of observational studies. Respirology. 2016;21(2):269–279. doi:10.1111/resp.12661
   PubMed Web of Science ®Google Scholar
• Wu CC, Rau KM, Lee WC, et al. Presence of Chronic Obstructive Pulmonary Disease (COPD) impair survival in lung cancer patients receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): a nationwide, population-based cohort study. J Clin Med. 2019;8(7):1024. doi:10.3390/jcm8071024
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Im Y, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019;145(9):2433–2439. doi:10.1002/ijc.32235
   PubMed Web of Science ®Google Scholar
• Sawa K, Koh Y, Kawaguchi T, et al. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: a comprehensive mutational analysis from a multi-institutional cohort. Lung Cancer. 2017;112:96–101. doi:10.1016/j.lungcan.2017.07.039
   PubMed Web of Science ®Google Scholar
• Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890. doi:10.1093/bioinformatics/bty560
   PubMed Web of Science ®Google Scholar
• Hwang KB, Lee IH, Li H, et al. Comparative analysis of whole-genome sequencing pipelines to minimize false negative findings. Sci Rep. 2019;9(1):3219. doi:10.1038/s41598-019-39108-2
   PubMed Web of Science ®Google Scholar
• Lai Z, Markovets A, Ahdesmaki M, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108. doi:10.1093/nar/gkw227
   PubMed Web of Science ®Google Scholar
• Li Q, Wang K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–280. doi:10.1016/j.ajhg.2017.01.004
   PubMed Web of Science ®Google Scholar
• Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873. doi:10.1371/journal.pcbi.1004873
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, Stehr H, et al. FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics. 2014;30(23):3390–3393. doi:10.1093/bioinformatics/btu549
   PubMed Web of Science ®Google Scholar
• Williams GH, Nicholson AG, Snead DRJ, et al. Interobserver reliability of programmed cell death ligand-1 scoring using the VENTANA PD-L1 (SP263) assay in NSCLC. J Thorac Oncol. 2020;15(4):550–555. doi:10.1016/j.jtho.2019.11.010
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun. 2019;39(1):79. doi:10.1186/s40880-019-0427-z
   Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Caramori G, Ruggeri P, Mumby S, et al. Molecular links between COPD and lung cancer: new targets for drug discovery? Expert Opin Ther Targets. 2019;23(6):539–553. doi:10.1080/14728222.2019.1615884
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Y, Guan Y, et al. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors. Mol Oncol. 2020;14(9):2096–2110. doi:10.1002/1878-0261.12739
   PubMed Web of Science ®Google Scholar
• Jin Y, Chen DL, Wang F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19(1):154. doi:10.1186/s12943-020-01274-7
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen J, Ren D, et al. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. Aging. 2020;13(1):598–618. doi:10.18632/aging.202169
   PubMedGoogle Scholar
• Chen H, Chong W, Wu Q, et al. Association of LRP1B Mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades. Front Immunol. 2019;10:1113. doi:10.3389/fimmu.2019.01113
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang J, Chen Y, et al. MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan-cancer. Clin Transl Med. 2020;10(4):e155. doi:10.1002/ctm2.155
   PubMed Web of Science ®Google Scholar
• Fang W, Ma Y, Yin JC, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to Anti-PD-(L)1 therapies in non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5015–5026. doi:10.1158/1078-0432.Ccr-19-0585
   PubMed Web of Science ®Google Scholar
• Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2):1900651. doi:10.1183/13993003.00651-2019
   PubMed Web of Science ®Google Scholar
• Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer. 2013;13(4):233–245. doi:10.1038/nrc3477
   PubMed Web of Science ®Google Scholar
• MacPherson S, Kilgour M, Lum JJ. Understanding lymphocyte metabolism for use in cancer immunotherapy. Febs j. 2018;285(14):2567–2578. doi:10.1111/febs.14454
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341–355. doi:10.1038/s41571-019-0173-9
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/s0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194. doi:10.1016/j.critrevonc.2020.103194
   PubMed Web of Science ®Google Scholar
• Bai H, Duan J, Li C, et al. EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. J Immunother Cancer. 2020;8(2):e001315. doi:10.1136/jitc-2020-001315
   PubMed Web of Science ®Google Scholar
• Yang MH, Yen CH, Chen YF, et al. Somatic mutations of PREX2 gene in patients with hepatocellular carcinoma. Sci Rep. 2019;9(1):2552. doi:10.1038/s41598-018-36810-5
   PubMed Web of Science ®Google Scholar
• Biton J, Ouakrim H, Dechartres A, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018;198(7):928–940. doi:10.1164/rccm.201706-1110OC
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. doi:10.1038/s41568-019-0179-8
   PubMed Web of Science ®Google Scholar
• Xu F, Lin H, He P, et al. A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. Oncoimmunology. 2020;9(1):1731943. doi:10.1080/2162402x.2020.1731943
   PubMed Web of Science ®Google Scholar
• VanderLaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer. 2017;106:17–21. doi:10.1016/j.lungcan.2017.01.011
   PubMed Web of Science ®Google Scholar
• Inomata M, Azechi K, Takata N, et al. Association of tumor PD-L1 expression with the T790M mutation and progression-free survival in patients with EGFR-mutant non-small cell lung cancer receiving EGFR-TKI therapy. Diagnostics. 2020;10(12). doi:10.3390/diagnostics10121006
   Web of Science ®Google Scholar